Maurizio Zanetti

List of Publications by Year
in descending order

95	2,888	147801 31	189892 50
papers	citations	h-index	g-index

105	105	105	4384
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Unfolded Protein Response at the Tumor-Immune Interface. Frontiers in Immunology, 2022, 13, 823157.	4.8	11
2	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. PLoS ONE, 2021, 16, e0246731.	2.5	7
3	The 2021 FASEB Virtual Catalyst Conference on Extracellular and Organismal Proteostasis in Health and Disease, February 3â€4, 2021. FASEB Journal, 2021, 35, e21631.	0.5	1
4	Neoantigen Controversies. Annual Review of Biomedical Data Science, 2021, 4, 227-253.	6.5	9
5	The unfolded protein response links tumor aneuploidy to local immune dysregulation. EMBO Reports, 2021, 22, e52509.	4.5	22
6	miR-335-laden B Cell-Derived Extracellular Vesicles Promote SOX4-Dependent Apoptosis in Human Multiple Myeloma Cells. Journal of Personalized Medicine, 2021, 11, 1240.	2.5	2
7	PERK-mediated induction of microRNA-483 disrupts cellular ATP homeostasis during the unfolded protein response. Journal of Biological Chemistry, 2020, 295, 237-249.	3.4	33
8	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	3.7	20
9	IRE1Î± and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. Scientific Reports, 2020, 10, 8348.	3.3	13
10	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. PLoS Biology, 2020, 18, e3000687.	5.6	42
11	Ubi Maior Minor Cessat. Critical Reviews in Immunology, 2020, 40, 255-262.	0.5	0
12	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. , 2020, 18, e3000687.		0
13	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. , 2020, 18, e3000687.		0
14	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. , 2020, 18, e3000687.		0
15	IRE1Î± regulates macrophage polarization, PD-L1 expression, and tumor survival. , 2020, 18, e3000687.		0
16	Insidious communication amongst cancer cells. Molecular and Cellular Oncology, 2018, 5, e1356898.	0.7	0
17	Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo. Scientific Reports, 2018, 8, 17581.	3.3	14
18	Evolutionary Pressure against MHC Class II Binding Cancer Mutations. Cell, 2018, 175, 416-428.e13.	28.9	176

#	Article	IF	Citations
19	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	27.6	95
20	Chromosomal chaos silences immune surveillance. Science, 2017, 355, 249-250.	12.6	15
21	Neoantigen prediction and the need for validation. Nature Biotechnology, 2017, 35, 815-817.	17.5	69
22	Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells. Science Signaling, 2017, 10, .	3.6	84
23	A community affair in the tumor microenvironment. Oncotarget, 2017, 8, 106173-106174.	1.8	1
24	Tumor microenvironment on the move and the Aselli connection. Science Signaling, 2016, 9, fs13.	3.6	8
25	Immune modulation by ER stress and inflammation in the tumor microenvironment. Cancer Letters, 2016, 380, 227-236.	7.2	37
26	High-efficiency Generation of Multiple Short Noncoding RNA in B-cells and B-cell-derived Extracellular Vesicles. Molecular Therapy - Nucleic Acids, 2015, 4, e271.	5.1	2
27	Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. Journal of Immunology, 2015, 194, 2049-2056.	0.8	119
28	Cell-Nonautonomous ER Stress-Mediated Dysregulation of Immunity by Cancer Cells. , 2015, , 397-429.		0
29	Synthesis and delivery of short, noncoding RNA by B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20182-20187.	7.1	24
30	Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Cancer Letters, 2013, 329, 236-242.	7.2	16
31	Cellâ€extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells. Annals of the New York Academy of Sciences, 2013, 1284, 6-11.	3.8	18
32	Sensing hyperploidy and immune surveillance: A pas-de-deux. Cell Cycle, 2013, 12, 544-544.	2.6	0
33	A Janus-faced role of the unfolded protein response in antitumor immunity. OncoImmunology, 2013, 2, e23901.	4.6	4
34	Generation of more effective cancer vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 2543-2547.	3.3	11
35	Immune Surveillance from Chromosomal Chaos?. Science, 2012, 337, 1616-1617.	12.6	5
36	Lipocalin 2 in cancer: When good immunity goes bad. Cancer Letters, 2012, 316, 132-138.	7.2	96

#	Article	IF	Citations
37	Cell-Extrinsic Effects of Tumor ER Stress Imprint Myeloid Dendritic Cells and Impair CD8+ T Cell Priming. PLoS ONE, 2012, 7, e51845.	2.5	108
38	ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-Î²B-dependent manner. BMC Cancer, 2011, 11, 229.	2.6	52
39	Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6561-6566.	7.1	233
40	Tumor Stress Inside Out: Cell-Extrinsic Effects of the Unfolded Protein Response in Tumor Cells Modulate the Immunological Landscape of the Tumor Microenvironment. Journal of Immunology, 2011, 187, 4403-4409.	0.8	73
41	Endoplasmic reticulum stress drives a regulatory phenotype in human T-cell clones. Cellular Immunology, 2010, 266, 1-6.	3.0	30
42	Selected MicroRNAs Define Cell Fate Determination of Murine Central Memory CD8 T Cells. PLoS ONE, 2010, 5, e11243.	2.5	52
43	Identification of Immunogenic Peptides of the Self-Tumor Antigen: Our Experience with Telomerase Reverse Transcriptase. Methods in Molecular Biology, 2010, 651, 211-225.	0.9	1
44	Principles of Memory CD8 T-Cells Generation in Relation to Protective Immunity. Advances in Experimental Medicine and Biology, 2010, 684, 108-125.	1.6	18
45	Cutting Edge: Antigen Presentation to CD8 T Cells after Influenza A Virus Infection. Journal of Immunology, 2009, 182, 29-33.	0.8	28
46	Protection against Influenza A Virus by Memory CD8 T Cells Requires Reactivation by Bone Marrow-Derived Dendritic Cells. Journal of Immunology, 2008, 180, 4956-4964.	0.8	15
47	Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition. Cancer Research, 2008, 68, 8085-8093.	0.9	27
48	Reduced Protection from Simian Immunodeficiency Virus SIV _{mac251} Infection Afforded by Memory CD8 ⁺ T Cells Induced by Vaccination during CD4 ⁺ T-Cell Deficiency. Journal of Virology, 2008, 82, 9629-9638.	3.4	54
49	KDEL-Retained Antigen in B Lymphocytes Induces a Proinflammatory Response: A Possible Role for Endoplasmic Reticulum Stress in Adaptive T Cell Immunity. Journal of Immunology, 2008, 181, 256-264.	0.8	43
50	Immunization with transgenic B cells as APC induces memory Tâ€cell specific immunity in tolerant mice. FASEB Journal, 2008, 22, 1077.14.	0.5	0
51	Plasmid DNA And IL-4 Modulate Expression of MHC Class I And Costimulatory Molecules in B Lymphocytes. DNA and Cell Biology, 2007, 26, 148-159.	1.9	0
52	Telomerase immunity from bench to bedside: round one. Journal of Translational Medicine, 2007, 5, 12.	4.4	36
53	Immunity and protection, the unfolding of a tale. Immunologic Research, 2007, 38, 305-318.	2.9	1
54	TLR9-Independent Activation of B Lymphocytes by Bacterial DNA. DNA and Cell Biology, 2006, 25, 253-261.	1.9	16

#	Article	IF	Citations
55	T cell memory and protective immunity by vaccination: is more better?. Trends in Immunology, 2006, 27, 511-517.	6.8	47
56	Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood, 2006, 107, 1505-1512.	1.4	55
57	Ex VivoProgramming of Antigen-Presenting B Lymphocytes: Considerations on DNA Uptake and Cell Activation. International Reviews of Immunology, 2006, 25, 83-97.	3.3	6
58	T for two: When helpers need help. Autoimmunity Reviews, 2005, 4, 571-578.	5.8	11
59	CD8 T cell priming by B lymphocytes is CD4 help dependent. European Journal of Immunology, 2005, 35, 1360-1370.	2.9	26
60	CD4 T cells in tumor immunity. Seminars in Immunopathology, 2005, 27, 37-48.	4.0	82
61	Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans. Seminars in Immunopathology, 2005, 27, 87-104.	4.0	15
62	Vaccine-Induced CD8+Central Memory T Cells in Protection from Simian AIDS. Journal of Immunology, 2005, 175, 3502-3507.	0.8	79
63	The Cooperation between Two CD4 T Cells Induces Tumor Protective Immunity in MUC.1 Transgenic Mice. Journal of Immunology, 2005, 175, 6551-6559.	0.8	19
64	In utero DNA immunizationImmunity over tolerance in fetal life. Vaccine, 2005, 23, 4273-4282.	3.8	7
65	T cell immunity using transgenic B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3892-3897.	7.1	38
66	B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunological Reviews, 2004, 199, 264-278.	6.0	38
67	Antigenized antibodies expressing Vbeta8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis. Journal of Immune Based Therapies and Vaccines, 2004, 2, 9.	2.4	6
68	Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. European Journal of Immunology, 2004, 34, 2331-2341.	2.9	25
69	Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. Vaccine, 2004, 23, 699-708.	3.8	36
70	Role of Tâ€„cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. European Journal of Immunology, 2003, 33, 720-728.	2.9	26
71	The Role of relB in Regulating the Adaptive Immune Response. Annals of the New York Academy of Sciences, 2003, 987, 249-257.	3.8	63
72	CD4 T cell priming in dendritic cell-deficient mice. International Immunology, 2003, 15, 127-136.	4.0	19

#	Article	IF	Citations
73	Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12275-12280.	7.1	88
74	Circumvention of MHC class II restriction by genetic immunization. Vaccine, 2001, 20, 630-634.	3.8	2
75	Studies on CD4 T Cell Immunity Using Somatic Transgene Immunization. International Reviews of Immunology, 2001, 20, 613-625.	3.3	1
76	DNA immunization inrelB-deficient mice discloses a role for dendritic cells in IgMâ€‰â€‰â†’â€‰â€‰ IgG1 switchin vivo. European Journal of Immunology, 1998, 28, 516-524.	2.9	25
77	Somatic Transgene Immunization with DNA Encoding an Immunoglobulin Heavy Chain. DNA and Cell Biology, 1997, 16, 611-625.	1.9	35
78	Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization. Nature Biotechnology, 1997, 15, 876-881.	17.5	34
79	Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. Nature Biotechnology, 1997, 15, 882-886.	17.5	45
80	Major histocompatibility complex class I-restricted presentation of influenza virus nucleoprotein peptide by B lymphoma cells harboring an antibody gene antigenized with the virus peptide. European Journal of Immunology, 1995, 25, 776-783.	2.9	27
81	Antigenicity and Immunogenicity of Antigenized Antibodies. Studies on B and T Cells. International Reviews of Immunology, 1993, 10, 251-263.	3.3	4
82	Ontogeny of the Immune System and the Invisible Frontier to Immune Regulation. International Reviews of Immunology, 1992, 8, 209-218.	3.3	5
83	Ligand expression using antigenization of antibody: Principle and methods. ImmunoMethods, 1992, 1, 41-51.	0.8	12
84	Antigenized antibodies. Nature, 1992, 355, 476-477.	27.8	58
85	Theoretical and Practical Aspects of Antigenized Antibodies. Immunological Reviews, 1992, 130, 125-150.	6.0	18
86	Idiotypic Analysis of Human Anti-Topoisomerase I Autoantibodies. Autoimmunity, 1991, 10, 41-48.	2.6	5
87	Idiotypic Analysis of Human Anticentromere Autoantibodies. Autoimmunity, 1991, 9, 131-140.	2.6	5
88	CD4/Immunoglobulin Interaction: Implications for Immune Physiology and Autoimmunity. International Reviews of Immunology, 1991, 7, 237-244.	3.3	9
89	Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding. Protein Engineering, Design and Selection, 1990, 4, 215-220.	2.1	37
90	Molecular characterization of the VH region of murine autoantibodies from neonatal and adult BALB/c mice. European Journal of Immunology, 1989, 19, 453-457.	2.9	37

#	Article	IF	Citations
91	Early Ontogeny of Rheumatoid Factor Antibodies. Characterization of a Murine Neonatal Hybridoma Autoantibody to IgGl in BALB/c Mice. Autoimmunity, 1989, 4, 9-19.	2.6	1
92	Next Steps in the Evolution of Vaccinology. Progress in Vaccinology, 1989, , 451-466.	0.7	3
93	Perturbation of the Autoimmune Network. I. Immunization with Anti-Idiotypic Antibodies Prior to Challenge with Antigen Induces Quantitative Variations in the Autoantibody Response. Autoimmunity, 1988, 1, 23-36.	2.6	6
94	The immunology of new generation vaccines. Trends in Immunology, 1987, 8, 18-25.	7.5	79
95	Disulfiram's journey from rubber vulcanization to Tâ€cell activation. EMBO Journal, 0, , .	7.8	0